CIViC Evidence Items

265 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline

BClinical — prospective trial or retrospective cohort study

CCase study — single case report or small case series

DPreclinical — in vitro or animal model data

EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

	Predictive	Diagnostic	Prognostic	Functional	Predispos.	Oncogenic
BCR::ABL1	323	11
BRAF	186	4	26	2		1
EGFR	248		12	3		2
EML4::ALK	64
ERBB2	142		2
FLT3	55	2	21
KIT	102	3	7
KRAS	159	4	24			4
PIK3CA	156		16	4
PTEN	53	1	3	1	2	1
TP53	52		40	100	2
VHL	5	2	3		635	15

Predictive:Links a variant to treatment response or resistance

Diagnostic:Supports or refutes a specific disease diagnosis

Prognostic:Informs disease progression or clinical outcome

Functional:Characterises the biological effect of a variant

Predisposing:Germline variant associated with cancer predisposition

Oncogenic:Characterises the variant's role in oncogenesis

Level	Gene	Variant	Type	Direction	Significance	Disease	Drugs	Source
B	EGFR	Exon 19 Deletion	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Afatinib	Yang et al., 2012
B	EGFR	L858R	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Afatinib	Yang et al., 2012
B	EGFR	Exon 19 Deletion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib	Rosell et al., 2012
B	EGFR	L858R	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib	Rosell et al., 2012
B	EGFR	Amplification	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Cetuximab	Personeni et al., 2008
B	EGFR	Y1092 PHOSPHORYLATION	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	Wang et al., 2012
B	EGFR	Overexpression	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib	Dziadziuszko et al., 2006
D	EGFR	T790M	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Osimertinib	Cross et al., 2014
B	EGFR	C797S	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Osimertinib	Thress et al., 2015
B	EGFR	T790M	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Osimertinib	Sequist et al., 2016
B	EGFR	VIII	Predictive	Supports	Sensitivity/Response	Glioblastoma	Rindopepimut	Schuster et al., 2015
D	EGFR	K467T	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Futuximab/Modotuximab Mixture,Panitumumab	Sánchez-Martín et al., 2016
D	EGFR	K467T	Predictive	Supports	Resistance	Colorectal Cancer	Cetuximab	Sánchez-Martín et al., 2016
C	EGFR	P753S	Predictive	Supports	Sensitivity/Response	Skin Squamous Cell Carcinoma	Sirolimus,Cetuximab	Ganesan et al., 2016
B	EGFR	VIII	Predictive	Supports	Sensitivity/Response	Glioblastoma	Gefitinib,Erlotinib	Mellinghoff et al., 2005
B	EGFR	T790M	Predictive	Supports	Resistance	Lung Adenocarcinoma	Gefitinib,Erlotinib	Yu et al., 2013
C	EGFR	S768I	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Erlotinib	Hellmann et al., 2014
B	EGFR	L858R	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib	Yang et al., 2008
B	EGFR	Exon 19 Deletion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib	Yang et al., 2008
B	EGFR	T790M	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	Belchis et al., 2016
B	EGFR	G719S	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib,Erlotinib	Otsuka et al., 2015
C	EGFR	D761Y	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Gefitinib,Erlotinib	Balak et al., 2006
C	EGFR	S720	Predictive	Supports	Resistance	Lung Adenocarcinoma	Erlotinib	Klughammer et al., 2016
C	EGFR	K757R	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Erlotinib	Klughammer et al., 2016
C	EGFR	V769_D770insASV	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Erlotinib	Klughammer et al., 2016
B	EGFR	Exon 20 Insertion	Predictive	Supports	Resistance	Lung Adenocarcinoma	Afatinib	Yang et al., 2015
B	EGFR	T790M	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Gefitinib	Kosaka et al., 2006
D	EGFR	T790M	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Dacomitinib	Engelman et al., 2007
C	EGFR	E746_A750del	Predictive	Supports	Sensitivity/Response	Bronchiolo-alveolar Adenocarcinoma	Erlotinib	Pao et al., 2004
B	EGFR	Exon 19 Deletion	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Gefitinib	Han et al., 2012
B	EGFR	Mutation	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib	Pao et al., 2004
D	EGFR	L858R	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Lapatinib	Li et al., 2008
D	EGFR	L858R	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Dacomitinib	Engelman et al., 2007
D	EGFR	L858R	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Neratinib	Shimamura et al., 2006
D	EGFR	L858R	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Canertinib	Li et al., 2008
B	EGFR	L858R	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Gefitinib	Han et al., 2012
D	EGFR	Amplification	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Rociletinib,Osimertinib	Nukaga et al., 2017
B	EGFR	Mutation	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib	Douillard et al., 2010
B	EGFR	Mutation	Prognostic	Supports	Better Outcome	Lung Adenocarcinoma		Brugger et al., 2011
B	EGFR	Mutation	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib	Pao et al., 2004
C	EGFR	L861Q	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib	Wu et al., 2011
D	EGFR	T790M	Predictive	Supports	Resistance	Cancer	Gefitinib,Multikinase Inhibitor AEE788,Erlotinib	Kancha et al., 2009
D	EGFR	L858R	Predictive	Supports	Sensitivity/Response	Cancer	Gefitinib,Multikinase Inhibitor AEE788,Erlotinib	Kancha et al., 2009
D	EGFR	R108K	Predictive	Supports	Sensitivity/Response	High Grade Glioma	Erlotinib	Lee et al., 2006
D	EGFR	T263P	Predictive	Supports	Sensitivity/Response	High Grade Glioma	Erlotinib	Lee et al., 2006
D	EGFR	A289V	Predictive	Supports	Sensitivity/Response	High Grade Glioma	Erlotinib	Lee et al., 2006
B	EGFR	G719	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	Wu et al., 2011
C	EGFR	G719D	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	Wu et al., 2011
C	EGFR	V774A	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib	Wu et al., 2011
C	EGFR	V834I	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib	Wu et al., 2011

Page 3 of 6

Previous Next